AQEMIA
The AI engine Fit Assessment
BetaAqemia effectively utilizes machine learning and quantum algorithms to discover new drug candidates, significantly optimizing the drug discovery process.
Blurb
Drug discovery - Pharma 3.0
HQ Location
France
Founded
2019
Employees
11 - 50
Total funding raised
$64.10M
Last Funding Event
Series A, $32.53M, January 30, 2024
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
Developer of a drug discovery platform designed to discover new drugs for specific therapeutic targets. The company's platform combines machine learning and quantum-inspired statistical mechanics algorithms to generate lead-like molecules for a given target, enabling researchers to efficiently and accurately predict the affinity between drug candidates and therapeutic targets.